We have read with great interest the article entitled “Time to update evidence-based guideline recommendations about concurrent tamoxifen and antidepressant use? A systematic review,”
1conducted by Michelle Bradbury and collaborators and published in Clinical Breast Cancer last April. The authors searched for studies within MEDLINE, EMBASE, and the Cochrane Collaboration Library published from database inception until December 1, 2020, including 15 studies: 2 randomized controlled trials (255 patients), 10 retrospective cohort studies (75,678 patients), and 3 case-control studies (18,836 patients). Outcomes of interest included recurrence, breast cancer-specific survival, overall mortality, quality of life, and treatment compliance. Tamoxifen and antidepressants showed no consistent negative effect on clinical outcomes, suggesting lack of clinical importance for this hypothetical drug-drug interaction (DDI). The authors also presented a summary of current guidelines on recommended SSRI/SNRI use with concomitant tamoxifen, providing a link between research and clinical recommendations.
- Bradbury M
- Hutton B
- Beltran-Bless AA
- et al.
Time to update evidence-based guideline recommendations about concurrent tamoxifen and antidepressant use? A systematic review.
Clin Breast Cancer. 2022; 22: e362-e373
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Clinical Breast Cancer
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Time to update evidence-based guideline recommendations about concurrent tamoxifen and antidepressant use? A systematic review.Clin Breast Cancer. 2022; 22: e362-e373
- Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen.Breast J. 2006; 12: 114-122
- Treatment of depressive symptoms in breast cancer patients undergoing adjuvant therapy.J Clin Oncol. 2013; 31: 9631
- Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence.Breast Cancer Res Treat. 2011; 126: 695-703
- Selective serotonin reuptake inhibitor use and breast cancer survival: a population-based cohort study.Breast Cancer Res. 2018; 20: 4
- Breast cancer recurrence risk in relation to antidepressant use after diagnosis.Breast Cancer Res Treat. 2008; 112: 123-132
- Breast cancer recurrence in relation to antidepressant use.Cancer Causes Control. 2016; 27: 125-136
- Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer.J Clin Oncol. 2010; 28: 2423-2429
- Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors: multi-database cohort study.BMJ. 2016; 354: I5014
- CYP2D6-inhibiting medication use and inherited CYP2D6 variation in relation to adverse breast cancer outcomes after tamoxifen therapy.Cancer Causes Control. 2019; 30: 103-112
- Potent CYP2D6 inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen.Breast Cancer Res Treat. 2011; 125: 505-510
- Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram.Br J Cancer. 2008; 99: 616-621
- Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen.Acta Oncol. 2010; 49: 305-312
- Effect of selective serotonin reuptake inhibitors use on endocrine therapy adherence and breast cancer mortality: a population-based study.Breast Cancer Res Treat. 2016; 159: 293-303
- Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study.BMJ. 2010; 340: c693https://doi.org/10.1136/bmj.c693
- Tamoxifen and antidepressant drug interaction in a cohort of 16,887 breast cancer survivors.J Natl Cancer Inst. 2016; 108: djv337
- CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.J Natl Cancer Inst. 2011; 103: 489-500
Published online: December 27, 2022
Accepted: December 23, 2022
Received: December 14, 2022
© 2023 Elsevier Inc. All rights reserved.